medigraphic.com
ISSN 2992-7749 (Electronic)
ISSN 2992-7897 (Print)
Órgano Oficial de difusión científica de la Asociación Mexicana de Cirujanos de Columna A. C.

2023, Number 4

<< Back Next >>

Cir Columna 2023; 1 (4)

Management of spinal chordoma with denosumab

Bazán PL, Cinalli M, Cepeda JR

Language: Spanish
References: 29
Page: 232-236
PDF size: 140.76 Kb.


ABSTRACT

Introduction: chordoma is a malignant tumor of very low frequency, the gold standard of treatment is en bloc resection, but its management when this is impossible or in recurrence is not clear. In recent years, the use of denosumab in bone defects associated with primary or metastatic bone tumors has been expanded. Denosumab, a human monoclonal antibody with antiresorptive function, was licensed in 2013 for the treatment of giant cell tumor and is being evaluated for other bone tumors. The aim of this study was to evaluate the use of denosumab in the adjuvant pharmacological treatment of symptomatic, inoperable or recurrent chordomas. Material and methods: systematic review, using the MeSH term "chordoma" AND "drug therapy", and the inclusion criterion of justification for the use of denosumab. Results: 15 articles were initially selected with only one that met the inclusion criteria, where 12 chordomas out of a total of 199 primary bone tumors were evaluated, which were measured for sRANK, RANKL and OPG. Chordoma has high RANK levels and low RANKL levels. This makes the use of denosumab possible. Conclusions: due to the number of RANK/RANKL receptors present in the chordoma, it may be susceptible to the response of the use of denosumab, lacking more clinical studies for its strong recommendation.


REFERENCES

  1. Martínez Tello FJ, Conde Gallego E, Manjón Luengo P, Rico y Campo JR, Pérez Barrios A. Cordoma. Sus variantes y diagnóstico diferencial. Rev Esp Patol. 2007; 40: 135-145.

  2. Salisbury JR. Embryology and pathology of the human notochord. Ann Pathol. 2001; 21: 479-488.

  3. Kayani B, Hanna SA, Sewell MD, Saifuddin A, Molloy S, Briggs TW. A review of the surgical management of sacral chordoma. Eur J Surg Oncol. 2014; 40: 1412-1420. doi: 10.1016/j.ejso.2014.04.008.

  4. Kayani B, Sewell MD, Tan KA, Hanna SA, Williams R, Pollock R, et al. Prognostic factors in the operative management of sacral chordomas. World Neurosurg. 2015; 84: 1354-1361. doi: 10.1016/j.wneu.2015.06.030.

  5. Larrier N, Eward WC, Riedel RF. Bone sarcomas. In: Cancer consult: expertise for clinical practice. New York: John Wiley and Sons, Inc; 2014. pp. 687-695.

  6. Chandawarkar RY. Sacrococcygeal chordoma: review of 50 consecutive patients. World J Surg. 1996; 20: 717-719. doi: 10.1007/s002689900110.

  7. Stephens GC, Schwartz HS. Lumbosacral chordoma resection: image integration and surgical planning. J Surg Oncol. 1993; 54: 226-232. doi: 10.1002/jso.2930540408.

  8. Ozaki T, Hillmann A, Winkelmann W. Surgical treatment of sacrococcygeal chordoma. J Surg Oncol. 1997; 64: 274-279.

  9. Bazán PL, Terraza S, Borri AR, Medina M. Sacrectomía parcial por abordaje posterior único. Rev Asoc Argent Ortop Traumatol. 2017; 82: 109-115.

  10. Germscheid NM, Fisher CG. Focus issue II in spine oncology: compendium of spine oncology recommendations. Spine (Phila Pa 1976). 2016; 41 Suppl 20: S163-S170.

  11. Lam FC, Arle JE, Glazer PA, Kasper EM. Primary extradural tumors of the spine - case review with evidence-guided management. Surg Neurol Int. 2014; 5: S373-S375.

  12. Frezza AM, Botta L, Trama A, Dei Tos AP, Stacchiotti S. Chordoma: update on disease, epidemiology, biology and medical therapies. Curr Opin Oncol. 2019; 31: 114-120. doi: 10.1097/CCO.0000000000000502.

  13. Rodríguez M, Casales N, Silveri C, Cardozo J, Filomeno P, Francescoli L. Denosumab, tratamiento alternativo en tumor óseo de células gigantes. Rev Med Urug. 2017; 33:152-155.

  14. Gossai N, Hilgers MV, Polgreen LE, Greengard EG. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer. 2015; 62: 1078-1080. doi: 10.1002/pbc.25393.

  15. Patel RS, Dhamne CA, Gopinathan A, Kumar N, Kumar N. Denosumab: a potential treatment option for aneurysmal bone cyst of the atlas. Eur Spine J. 2018; 27: 494-500. doi: 10.1007/s00586-018-5528-x.

  16. Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019; 20: 1719-1729. doi: 10.1016/S1470-2045(19)30663-1.

  17. Kushlinskii NE, Gershtein ES, Solov'ev YN, Timofeev YS, Babkina IV, Dolinkin AO, et al. Receptor activator of nuclear transcription factor NF-κB (RANK), its ligand RANKL, and natural inhibitor of RANKL osteoprotegerin (OPG) in the blood serum of patients with primary bone tumors. Bull Exp Biol Med. 2017; 163: 478-481. doi: 10.1007/s10517-017-3832-9.

  18. Bazán PL, Di Falco R, Borri AE, Medina M, Ciccioli NM, Danielle S. The use of denosumab in giant cell tumors in sacrum. Coluna/Columna. 2020; 19: 147-149. doi: 10.1590/S1808-18512020190228839.

  19. Yonezawa N, Murakami H, Demura S, Kato S, Yoshioka K, Takeuchi A, et al. Morphologic changes after denosumab therapy in patients with giant cell tumor of the spine: report of four cases and a review of the literature. World Neurosurg. 2019; 127: 38-46. doi: 10.1016/j.wneu.2019.03.185.

  20. Gilani A, Kleinschmidt-DeMasters BK. Denosumab therapy obscures histological features of giant cell tumor of bone. J Neuropathol Exp Neurol. 2019; 78: 1171-1173. doi: 10.1093/jnen/nlz100.

  21. Urakawa H, Mizusawa J, Tanaka K, Eba J, Hiraga H, Kawai A, et al. A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610. Jpn J Clin Oncol. 2019; 49: 379-382. doi: 10.1093/jjco/hyz004.

  22. Dürr HR, Grahneis F, Baur-Melnyk A, Knosel T, Birkenmaier C, Jansson V, et al. Aneurysmal bone cyst: results of an off label treatment with denosumab. BMC Musculoskelet Disord. 2019; 20: 456. doi: 10.1186/s12891-019-2855-y.

  23. Lanari Zubiaur F, Godoy A, Bazán PL. Use of denosumab in vertebral giant cell tumor. Rev Asoc Argent Ortop Traumatol. 2021; 86: 821-828. doi: 10.15417/issn.1852-7434.2021.86.6.1121.

  24. Barbanti-Brodano G, Girolami M, Ghermandi R, Terzi S, Gasbarrini A, Bandiera S, et al. Aneurysmal bone cyst of the spine treated by concentrated bone marrow: clinical cases and review of the literature. Eur Spine J. 2017; 26: 158-166. doi: 10.1007/s00586-017-4978-x.

  25. Ntalos D, Priemel M, Schlickewei C, Thiesen DM, Rueger JM, Spiro AS. Therapeutic management of a substantial pelvic aneurysmatic bone cyst including the off-label use of denosumab in a 35-year-old female patient. Case Rep Orthop. 2017; 2017: 9125493. doi: 10.1155/2017/9125493.

  26. Deveci MA, Paydas S, Gonlüsen G, Ozkan C, Bicer OS, Tekin M. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: prospective study of 14 cases. Acta Orthop Traumatol Turc. 2017; 51: 1-6. doi: 10.1016/j.aott.2016.03.004.

  27. Bazán PL, Cinalli M, Zabiaur FL, Castelli R, Silveri C, Monayer JL, et al. Uso prolongado de denosumab en tumor de células gigantes y quistes óseos aneurismáticos vertebrales. Coluna/Columna. 2022; 21: e253789. doi: 10.1590/S1808-185120201902228839.

  28. Redondo A, Bagué S, Bernabeu D, Ortiz-Cruz E, Valverde C, Alvarez R, et al. Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). Cancer Chemother Pharmacol. 2017; 80: 1113-1131. doi: 10.1007/s00280-017-3436-0.

  29. Colia V, Stacchiotti S. Medical treatment of advanced chordomas. Eur J Cancer. 2017; 83: 220-228. doi: 10.1016/j.ejca.2017.06.038.




2020     |     www.medigraphic.com